Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China
· Delayed Price · Currency is CNY 43.45
-0.56 (-1.27%)
Mar 9, 2026, 3:04 PM CST
Betta Pharmaceuticals Revenue
Betta Pharmaceuticals had revenue of 985.93M CNY in the quarter ending September 30, 2025, with 16.83% growth. This brings the company's revenue in the last twelve months to 3.26B, up 18.40% year-over-year. In the year 2024, Betta Pharmaceuticals had annual revenue of 2.89B with 17.74% growth.
Revenue (ttm)
3.26B
Revenue Growth
+18.40%
P/S Ratio
5.60
Revenue / Employee
1.66M
Employees
1,961
Market Cap
18.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.89B | 435.75M | 17.74% |
| Dec 31, 2023 | 2.46B | 79.57M | 3.35% |
| Dec 31, 2022 | 2.38B | 130.77M | 5.82% |
| Jan 1, 2022 | 2.25B | 375.59M | 20.08% |
| Dec 31, 2020 | 1.87B | 316.34M | 20.36% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Walvax Biotechnology | 2.40B |
| China Resources Double-Crane Pharmaceutical | 10.95B |
| Shandong Buchang Pharmaceuticals | 10.96B |
| Tonghua Dongbao Pharmaceutical | 2.74B |
| Zhejiang Medicine | 8.96B |
| Wedge Industrial | 1.24B |
| Fujian Cosunter Pharmaceutical | 430.98M |
| Apeloa Pharmaceutical Co.,Ltd | 10.50B |
Betta Pharmaceuticals News
- 5 months ago - Chinese healthcare, biotech firms flock to Hong Kong for IPOs - South China Morning Post